To compare bone mineral density ( BMD ) changes over @ weeks in adults virologically failing standard first-line therapy , randomized to raltegravir plus lopinavir/ritonavir ( RAL + LPV/r ) or conventional @-@ nucleoside/nucleotide reverse transcriptase inhibitors -LSB- N ( t ) RTIs -RSB- + LPV/r second-line therapy .